LBF20107PG20: Difference between revisions
No edit summary |
No edit summary |
||
| (19 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{Lipid/Header}} | |||
{{Hierarchy|{{PAGENAME}}}} | {{Hierarchy|{{PAGENAME}}}} | ||
| Line 4: | Line 6: | ||
|LipidBank=XPR1799 | |LipidBank=XPR1799 | ||
|LipidMaps=LMFA03010128 | |LipidMaps=LMFA03010128 | ||
|SysName=6R, | |SysName=(6R,9alpha) -Epoxy- (11alpha,15S) -dihydroxy-prost-trans-13-en-1-oic acid | ||
|Common Name=&& | |Common Name=&&6alpha-Prostaglandin I_1&&(6R,9alpha) -Epoxy- (11alpha,15S) -dihydroxy-prost-13(E)-en-1-oic acid&& | ||
|Source= | |||
|Chemical Synthesis= | |||
|Metabolism= | |||
|Biological Activity=6 alpha -PGI1 is reported to promote cAMP accumulation in human thyroied slices and cells in a concentration dependent manner.[[Reference:Leighton_JK:DeBrunner-Vossbrinck_BA:Kemper_B:,Biochemistry,1984,23,204|{{RelationTable/GetFirstAuthor|Reference:Leighton_JK:DeBrunner-Vossbrinck_BA:Kemper_B:,Biochemistry,1984,23,204}}]] And also exhibits 6 alpha -PGI1 inhibition of ADP-induced platelet aggregation at the IC50 value of 350 ng/ml.[[Reference:Whittle_BJ:Moncada_S:,Adv. Exp. Med. Biol.,1984,164,193|{{RelationTable/GetFirstAuthor|Reference:Whittle_BJ:Moncada_S:,Adv. Exp. Med. Biol.,1984,164,193}}]] | |||
}} | }} | ||
{{Lipid/Footer}} | |||
Latest revision as of 17:15, 21 October 2010
| LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
| IDs and Links | |
|---|---|
| LipidBank | XPR1799 |
| LipidMaps | LMFA03010128 |
| CAS | |
| KEGG | {{{KEGG}}} |
| KNApSAcK | {{{KNApSAcK}}} |
| mol | LBF20107PG20 |
| 6α-Prostaglandin I1 | |
|---|---|
| |
| Structural Information | |
| (6R,9α) -Epoxy- (11α,15S) -dihydroxy-prost-trans-13-en-1-oic acid | |
| |
| Formula | C20H34O5 |
| Exact Mass | 354.240624198 |
| Average Mass | 354.48096000000004 |
| SMILES | C(CC[C@H](O)C=C[C@H]([C@H]12)[C@H](O)C[C@H](O[C@@H](C2)CCCCC(O)=O)1)CC |
| Physicochemical Information | |
| 6 alpha -PGI1 is reported to promote cAMP accumulation in human thyroied slices and cells in a concentration dependent manner. Leighton_JK et al. And also exhibits 6 alpha -PGI1 inhibition of ADP-induced platelet aggregation at the IC50 value of 350 ng/ml. Whittle_BJ et al. | |
| Spectral Information | |
| Mass Spectra | |
| UV Spectra | |
| IR Spectra | |
| NMR Spectra | |
| Other Spectra | |
| Chromatograms | |
| Reported Metabolites, References | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
